ID
45474
Description
Principal Investigator: E. Ann Coleman, University of Arkansas for Medical Sciences Little Rock, Arkansas, USA MeSH: Multiple Myeloma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000545 We hypothesized that genetic variability in the enzymes/proteins involved in drug metabolism, inflammation, and immune function is a major underlying contributor to mucositis incidence and progression and that, based on this variability we can identify variants that influence risk, and develop a mucositis progression prediction model that improves on existing models by incorporating genetic variability along with clinical factors. Using genome wide association study (GWAS) combined with a pathway candidate gene approach and a modified case-control study method, we investigated the hypothesis in a sample of 1092 patients who received a myeloablative dose of melphalan (MEL) followed by autologous hematopoietic stem cell (ASCT) transplantation as treatment for multiple myeloma and for whom banked blood stem cell samples and clinical data were available.
Lien
Mots-clés
Versions (2)
- 31/10/2022 31/10/2022 - Simon Heim
- 13/12/2022 13/12/2022 - Kristina Keller
Détendeur de droits
E. Ann Coleman, University of Arkansas for Medical Sciences Little Rock, Arkansas, USA
Téléchargé le
13 décembre 2022
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
dbGaP phs000545 Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors
Subject ID, age, type of cancer, BMI, body surface area, weight, gender, race, hematocrit, hemoglobin, GFR, creatinine, albumin, c-reactive protein, Melphelan dose, beta-microglobulin, myeloma isotype, mucositis grade, and CMV of participants involved in the "Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants involved in the "Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors" project.
- Subject ID, sample ID, sample source, sample source ID, and sample use variable associated with participants involved in the "Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors" project.
- Subject ID, age, type of cancer, BMI, body surface area, weight, gender, race, hematocrit, hemoglobin, GFR, creatinine, albumin, c-reactive protein, Melphelan dose, beta-microglobulin, myeloma isotype, mucositis grade, and CMV of participants involved in the "Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors" project.
- Subject ID, body site where sample was obtained, histological type of sample, analyte type, and tumor status of sample obtained from participants involved in the "Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors" project.
Similar models
Subject ID, age, type of cancer, BMI, body surface area, weight, gender, race, hematocrit, hemoglobin, GFR, creatinine, albumin, c-reactive protein, Melphelan dose, beta-microglobulin, myeloma isotype, mucositis grade, and CMV of participants involved in the "Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants involved in the "Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors" project.
- Subject ID, sample ID, sample source, sample source ID, and sample use variable associated with participants involved in the "Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors" project.
- Subject ID, age, type of cancer, BMI, body surface area, weight, gender, race, hematocrit, hemoglobin, GFR, creatinine, albumin, c-reactive protein, Melphelan dose, beta-microglobulin, myeloma isotype, mucositis grade, and CMV of participants involved in the "Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors" project.
- Subject ID, body site where sample was obtained, histological type of sample, analyte type, and tumor status of sample obtained from participants involved in the "Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors" project.
C2348585 (UMLS CUI [1,2])
C1274040 (UMLS CUI [1,2])
C0022885 (UMLS CUI [1,3])
C1522609 (UMLS CUI [1,4])
C3174092 (UMLS CUI [1,2])
C0021017 (UMLS CUI [1,2])
C3203348 (UMLS CUI [1,2])
C0226875 (UMLS CUI [1,2])
C0521585 (UMLS CUI [1,2])
C0872128 (UMLS CUI [1,3])
C0521585 (UMLS CUI [1,2])
C0872128 (UMLS CUI [1,3])
Aucun commentaire